The system (stock market, press, board) is incentivized to reward bold, confident-sounding restructuring narratives immediately. This short reward cycle means the announcement pays off financially before anyone can assess if the underlying strategy is sound.

After a large, debt-funded acquisition, deleveraging should be the top priority over share buybacks. Choosing buybacks sends a mixed signal, disappoints investors expecting a return to the growth playbook, and leaves the company too financially constrained to pursue future strategic M&A opportunities.

A primary cause of M&A failure is not financial misrepresentation but acquiring a key leader who lacks the "fire in their belly" to grow post-close. This undermines the deal thesis, especially when a high multiple was paid based on future growth potential.

Companies naturally deviate from their core values due to an unconscious influence called "financial gravity." This force alters behavior as leaders imagine what might please investors, leading to compromised decisions long before any direct pressure is applied.

Investment committees are adept at analyzing deal specifics like cash flow and competition. However, they systematically fail to discuss the more influential internal firm dynamics—such as pressure to deploy capital or individual biases—that are often the true cause of poor investment decisions and bad outcomes.

A significant, immediate drop in stock value following a merger rumor, like AstraZeneca's 8% fall, serves as a powerful de facto veto from investors. This signals strong disapproval of the strategic rationale, forcing management to reconsider the move or face shareholder rebellion.

Mergers and acquisitions are a means to accelerate a pre-existing strategy, not the objective itself. When conditions for a deal change unexpectedly, disciplined leaders must be willing to pivot from a full merger to a passive stake rather than force a flawed integration or admit defeat.

Deciding whether to invest more capital into a struggling portfolio company is a major point of conflict. The management team advocates strongly for the infusion, believing it can turn things around. However, investor experience shows that such 'bridge' rounds are rarely successful, making it a difficult decision.

Corporate leaders are incentivized and wired to pursue growth through acquisition, constantly getting bigger. However, they consistently fail at the strategically crucial, but less glamorous, task of divesting assets at the right time, often holding on until value has significantly eroded.